Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Assets (2017 - 2025)

Historic Assets for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $974.0 million.

  • Arcus Biosciences' Assets fell 2507.69% to $974.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $974.0 million, marking a year-over-year decrease of 2507.69%. This contributed to the annual value of $1.2 billion for FY2024, which is 502.28% up from last year.
  • Arcus Biosciences' Assets amounted to $974.0 million in Q3 2025, which was down 2507.69% from $1.1 billion recorded in Q2 2025.
  • Arcus Biosciences' 5-year Assets high stood at $1.6 billion for Q4 2021, and its period low was $839.3 million during Q3 2021.
  • Moreover, its 5-year median value for Assets was $1.2 billion (2024), whereas its average is $1.2 billion.
  • As far as peak fluctuations go, Arcus Biosciences' Assets soared by 43088.33% in 2021, and later tumbled by 2507.69% in 2025.
  • Over the past 5 years, Arcus Biosciences' Assets (Quarter) stood at $1.6 billion in 2021, then dropped by 18.34% to $1.3 billion in 2022, then decreased by 15.77% to $1.1 billion in 2023, then increased by 5.02% to $1.2 billion in 2024, then decreased by 15.3% to $974.0 million in 2025.
  • Its Assets stands at $974.0 million for Q3 2025, versus $1.1 billion for Q2 2025 and $1.2 billion for Q1 2025.